CAMPTH-1H

SCRI Development Innovations, LLC · Phase 2 active Small molecule

At a glance

Generic name	CAMPTH-1H
Sponsor	SCRI Development Innovations, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CAMPTH-1H CI brief — competitive landscape report
CAMPTH-1H updates RSS · CI watch RSS
SCRI Development Innovations, LLC portfolio CI